Saturday 17 October 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
0.48
0.02
−4.00%
Follow RDHL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 5 | 4 | 4 | 3 | 2 | 6 | 3 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.01 | 0.07 | 0.18 | 1.40 | 4.57 | 28.66 | 15.34 | 22.11 | 1,302.52 |
Altman Z-Score |
(24.39) | (33.41) | (22.61) | (5.14) | (3.38) | (1.94) | 2.59 | 2.01 | (0.89) | 5.00 |
Altman Z″-Score (non-manufacturers) |
(58.40) | (81.32) | (54.98) | (15.57) | (9.30) | (7.46) | (4.84) | (3.40) | (5.24) | 4.54 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(8.70) | 0.03 | 7.91 | (3.71) | (3.27) | 5.91 | (1.53) | (2.54) | 31.57 | — |
P/Operating CF |
(0.01) | (0.06) | (0.93) | (4.50) | (8.07) | (23.15) | (13.00) | (15.65) | (6.41) | (13.19) |
P/B ratio |
0.00 | 6.27 | 0.65 | 0.00 | 13.52 | 21.21 | 3.00 | 2.50 | 2.01 | 2.14 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.19 | 2.80 | 2.28 | 2.37 |
EV/Sales |
6.50 | 6.35 | 6.14 | 2.86 | 1.95 | 5.40 | 21.65 | 8.97 | 10.86 | 660.25 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(10.11) | (6.21) | (5.63) | (6.05) | (2.57) | (7.15) | (3.34) | (2.18) | (1.00) | (2.41) |
EV/FCF |
(2.72) | (2.29) | (2.16) | (2.13) | (1.41) | (3.39) | (3.24) | (2.11) | (0.97) | (2.27) |
Quick Ratio |
0.21 | 0.32 | 0.45 | 0.36 | 0.86 | 0.80 | 4.62 | 5.22 | 4.03 | 12.37 |
Current Ratio |
0.34 | 0.54 | 0.81 | 0.44 | 1.09 | 0.96 | 5.01 | 5.47 | 4.37 | 12.66 |
Net Debt/EBITDA |
0.53 | 0.79 | (0.43) | (2.28) | (0.75) | (0.86) | 1.04 | 1.36 | 0.89 | 2.17 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 72.52% | 47.04% | 46.10% | 5.15% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (2.38) | 9.60 | 5.99 | 0.06 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.39 | 0.07 | 0.36 | 0.47 | 0.51 | 0.09 | 0.14 | 0.06 | 0.00 |
Operating CF/Net income |
22.50 | 1.13 | (1.50) | 0.41 | 0.67 | 0.64 | 0.96 | 0.89 | 0.98 | 0.96 |
Capex/Depreciation |
(0.01) | (0.01) | (0.01) | (0.02) | (0.01) | (31.45) | (0.20) | (0.64) | (14.58) | (2.73) |
Interest Coverage |
(5.45) | (4.28) | 1.32 | (1.01) | (4.87) | (4.99) | (98.63) | (235.51) | (674.96) | (81.45) |
| 206.75% | 632.59% | (103.24%) | 362.65% | (859.70%) | (206.25%) | (76.09%) | (80.66%) | (84.52%) | (47.84%) | |
| (1.98%) | (40.24%) | 26.29% | (42.15%) | (54.09%) | (59.90%) | (61.98%) | (64.83%) | (69.24%) | (41.65%) | |
ROIC |
(1,671.30%) | 0.00% | 0.00% | (86.85%) | (90.38%) | (59.26%) | (169.34%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
3.39% | 81.24% | (655.23%) | 64.54% | (1,184.20%) | 3,417.36% | (98.78%) | (83.36%) | (113.64%) | (46.90%) |
Average Days of Receivables |
100.82 | 115.22 | 144.83 | 203.89 | 134.82 | 162.51 | 70.55 | 41.83 | 139.19 | 357.77 |
Research and Development Expense of Revenue |
707.34% | 19.74% | 54.03% | 11.78% | 34.40% | 25.62% | 276.89% | 297.39% | 822.79% | 24,991.09% |
Selling, General and Administrative Expense of Revenue |
2,158.04% | 60.76% | 474.35% | 103.61% | 102.60% | 116.01% | 473.92% | 239.14% | 500.10% | 5,349.50% |
Intangible Assets out of Total Assets |
0.21 | 0.31 | 0.24 | 0.41 | 0.40 | 0.49 | 0.23 | 0.09 | 0.09 | 0.08 |
Share Based Compensation of Revenue |
159.79% | 8.27% | 25.22% | 9.18% | 11.91% | 6.53% | 48.12% | 32.03% | 55.78% | 1,662.38% |
Graham Net Nets |
(161.27) | (16.36) | (2.01) | (11.13) | (0.69) | (0.33) | 0.22 | 0.36 | 0.43 | 0.42 |
Graham Number |
0.00 | 0.00 | 0.00 | 4,472.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(59,288.03%) | (9,833.60%) | (1,673.06%) | (639.15%) | (81.78%) | (26.49%) | (21.91%) | (31.71%) | (48.73%) | (21.44%) |
Free Cash Flow Yield |
(115,100.55%) | (22,118.96%) | (3,865.09%) | (758.96%) | (98.80%) | (34.80%) | (23.31%) | (27.76%) | (50.68%) | (22.30%) |
Revenue per Share |
0.09 | 6.53 | 25.20 | 1,003.25 | 1,844.24 | 1,768.10 | 211.82 | 361.90 | 226.38 | 7.83 |
Operating CF per Share |
(3.06) | (7.60) | (138.25) | (473.78) | (1,398.86) | (1,334.59) | (1,372.02) | (1,491.86) | (2,529.32) | (2,190.54) |
Capex per Share |
0.00 | (0.01) | (0.04) | (3.21) | (2.47) | (1,477.31) | (6.83) | (2.51) | (66.72) | (9.30) |
Free Cash Flow per Share |
(3.06) | (7.61) | (138.29) | (477.00) | (1,401.33) | (2,811.90) | (1,378.86) | (1,494.37) | (2,596.05) | (2,199.84) |
Cash per Share |
1.26 | 3.75 | 24.54 | 584.14 | 817.29 | 818.49 | 1,611.85 | 2,302.38 | 2,610.45 | 5,128.22 |
Shareholders Equity per Share |
1.35 | (3.80) | 7.99 | (785.71) | 190.86 | 380.88 | 2,020.27 | 2,215.84 | 2,546.05 | 4,860.54 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.35 | (3.80) | 7.99 | (785.71) | 190.86 | 380.88 | 2,020.27 | 2,215.84 | 2,546.05 | 4,860.54 |
Free Cash Flow |
(9.66) | (9.38) | (35.83) | (29.38) | (65.16) | (102.35) | (40.95) | (34.52) | (45.95) | (28.38) |
Working Capital |
(12.69) | (10.31) | (3.84) | (111.55) | 7.68 | (2.74) | 42.60 | 46.41 | 39.85 | 62.46 |
Capital Expenditures |
0.00 | (0.01) | (0.01) | (0.20) | (0.11) | (53.77) | (0.20) | (0.06) | (1.18) | (0.12) |
Net Current Asset Value |
(14.55) | (10.81) | (4.84) | (121.37) | (83.16) | (95.88) | 39.12 | 45.56 | 39.40 | 56.30 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.03 | 0.01 | 0.29 | 1.19 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
8.35 | 4.59 | 10.31 | 16.24 | 31.73 | 3.35 | 4.37 | 0.55 | 0.35 | 0.27 |
Cash ROIC |
(117.20%) | 14,209.09% | (425.14%) | (28.58%) | (49.32%) | (80.75%) | (36.67%) | (33.07%) | (50.35%) | (22.02%) |
Accounts Receivable Turnover |
0.22 | 3.14 | 0.35 | 1.87 | 2.84 | 4.31 | 5.79 | 6.73 | 4.93 | 0.09 |
Accounts Payable Turnover |
— | 1.44 | 0.92 | 4.19 | 4.26 | 4.69 | 0.60 | 0.70 | 0.87 | 0.00 |
Inventory Turnover |
— | 0.79 | 0.45 | 2.58 | 4.63 | 8.78 | 1.70 | 3.99 | 0.82 | — |
Average Days of Payables |
— | 133.56 | 345.90 | 46.31 | 86.17 | 114.30 | 676.03 | 427.66 | 824.94 | 0.00 |
Days of Inventory on Hand |
— | 417.49 | 463.14 | 120.54 | 109.41 | 64.57 | 304.09 | 98.94 | 112.11 | — |
Average Receivables |
1.31 | 2.57 | 18.56 | 33.10 | 30.17 | 14.94 | 1.09 | 1.24 | 0.81 | 1.18 |
Average Payables |
— | 2.22 | 3.75 | 7.95 | 11.61 | 7.87 | 3.75 | 4.06 | 2.43 | 1.79 |
Average Inventory |
— | 4.02 | 7.70 | 12.91 | 10.67 | 4.20 | 1.33 | 0.71 | 2.58 | — |
Average Assets |
21.69 | 20.55 | 90.96 | 170.03 | 180.71 | 127.17 | 68.26 | 59.88 | 65.78 | 70.52 |
Average Common Equity |
(0.21) | (1.31) | (23.17) | (19.76) | 11.37 | 36.93 | 55.59 | 48.13 | 53.88 | 61.39 |
Columns are period end dates · fundamentals updated 2 Oct 2026